More on ENTA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $11.24 |
|
|||
| Open | $11.33 | ||||
| 52 Wk High | $34.49 | ||||
| 52 Wk Low | $20.39 | ||||
| Day High | $11.99 | ||||
| Day Low | $11.33 | ||||
| P/E | N/A | ||||
| EPS | $-3.18 | ||||
| Volume | 208,573 | ||||
- Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
- Form S-8 ENANTA PHARMACEUTICALS
- Form 10-Q ENANTA PHARMACEUTICALS For: Mar 31
- Form 8-K ENANTA PHARMACEUTICALS For: May 11
- Enanta Pharma (ENTA) Tops Q2 EPS by 12c
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
- Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
- Enanta begins phase 1 trial of oral KIT inhibitor for urticaria
- Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
- Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Entities mentioned with ENTA
- Earnings | View Related Stories »
- FDA | View Related Stories »
- 13G | View Related Stories »
- Twitter | View Related Stories »
- JPMorgan | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
